Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety

Advances in Therapy

Volumn 26, Issue 11, 2009, Pages 1012-1023

  Calhoun, David A ^b   Crikelair, Nora A ^a   Yen, Joseph ^a   Glazer, Robert D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

Amlodipine; Antihypertensive; Blood pressure; Combination; Dual therapy; Hydrochlorothiazide; Hypertension; Triple therapy; Valsartan

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN; AMLODIPINE PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; UNCLASSIFIED DRUG; AMLODIPINE; DRUG DERIVATIVE; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EXERTIONAL DIZZINESS; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT;

ADOLESCENT; ADULT; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; TETRAZOLES; VALINE;

EID: 77949911629     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0077-7     Document Type: Article

References (27)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
2. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
3. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
4. Milani RV. Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy. Am J Manag Care. 2005;11(suppl. 7):S220-S227.
5. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
6. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008;10:185-194.
7. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, doubleblind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens. 2008;2:294-302.
8. Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixeddose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27:1013-1021.
9. Oparil S, Barr E, Elkins M, et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther. 1996;18:608-625. (Pubitemid 26323039)
10. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebocontrolled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580.
11. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279-289.
12. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61-73.
13. Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27:578-587.
14. Tuomilehto J, Tykarski A, Baumgart P, et al. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. Blood Press. 2008;1:15-23.
15. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187. (Pubitemid 46924065)
16. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent twopill therapy in patients with hypertension. Manag Care. 2000;9(suppl. 9):2-6.
17. Jackson JH, Sobolski J, Krienke R, et al. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. J Am Board Fam Med. 2008;21:512-521.
18. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54:32-39.
19. Weir MR. Assessing the blood pressure-lowering efficacy of antihypertensive medications: which blood pressures should we use? J Clin Hypertens (Greenwich). 2009;11:155-158.
20. Hense HW, Maziak W, Heidrich J. Why is blood pressure control unsatisfactory-or is it? Nephrol Dial Transplant. 2002;17:1547-1550.
21. Campo C, Segura J, Ruilope LM. Factors influencing the systolic blood pressure response to drug therapy. J Clin Hypertens (Greenwich). 2002;4:35-40.
22. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328:634-640. (Pubitemid 38340037)
23. Mugo MN, Sowers JR. Early and aggressive treatment of complex hypertension. J Clin Hypertens (Greenwich). 2005;7:8-10.
24. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-2051.
25. Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens. 2006;20:169-175.
26. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
27. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886. (Pubitemid 36677151)